Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

The Psychopharmacology Algorithm Project at the Harvard South Shore Program

An Update on Unipolar Nonpsychotic Depression

Giakoumatos, Christoforos Iraklis, MD; Osser, David, MD

doi: 10.1097/HRP.0000000000000197
Reviews
Buy
SDC

Background The Psychopharmacology Algorithm Project at the Harvard South Shore Program presents evidence-based recommendations considering efficacy, tolerability, safety, and cost. Two previous algorithms for unipolar nonpsychotic depression were published in 1993 and 1998. New studies over the last 20 years suggest that another update is needed.

Methods The references reviewed for the previous algorithms were reevaluated, and a new literature search was conducted to identify studies that would either support or alter the previous recommendations. Other guidelines and algorithms were consulted. We considered exceptions to the main algorithm, as for pregnant women and patients with anxious distress, mixed features, or common medical and psychiatric comorbidities.

Summary For inpatients with severe melancholic depression and acute safety concerns, electroconvulsive therapy (or ketamine if ECT refused or ineffective) may be the first-line treatment. In the absence of an urgent indication, we recommend trialing venlafaxine, mirtazapine, or a tricyclic antidepressant. These may be augmented if necessary with lithium or T3 (triiodothyronine). For inpatients with non-melancholic depression and most depressed outpatients, sertraline, escitalopram, and bupropion are reasonable first choices. If no response, the prescriber (in collaboration with the patient) has many choices for the second trial in this algorithm because there is no clear preference based on evidence, and there are many individual patient considerations to take into account. If no response to the second medication trial, the patient is considered to have a medication treatment–resistant depression. If the patient meets criteria for the atypical features specifier, a monoamine oxidase inhibitor could be considered. If not, reconsider (for the third trial) some of the same options suggested for the second trial. Some other choices can also considered at this stage. If the patient has comorbidities such as chronic pain, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, or posttraumatic stress disorder, the depression could be secondary; evidence-based treatments for those disorders would then be recommended.

From Harvard Medical School and VA Boston Healthcare System, Brockton Division, Brockton, MA.

Original manuscript received 4 December 2017, accepted for publication subject to revision 4 February 2017; revised manuscript received 4 March 2017.

Correspondence: Christoforos Iraklis Giakoumatos, MD, VA Boston Healthcare System, 940 Belmont St., Brockton, MA 02301. Email: cigiakoumatos@gmail.com

© 2019 President and Fellows of Harvard College
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website